X

Drug Profile

GEM 00220

Alternative Names: GEM-00220

Latest Information Update: 04 Apr 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Northern Therapeutics
Class Mesenchymal stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Septic shock

Most Recent Events

26 Mar 2024 Northern Therapeutics terminates a phase I trial in Septic shock in Canada (IV), considering funding decision (NCT04961658)
11 Aug 2021 Phase-I clinical trials in Septic shock in Canada (IV) (NCT04961658)
14 Jul 2021 Northern Therapeutics plans the phase I AMETHYST trial for Septic shock in Canada (IV) in July 2021 (NCT04961658)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com